Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Shares Bought by Sei Investments Co.

Sei Investments Co. lifted its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 25.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 26,818 shares of the specialty pharmaceutical company’s stock after acquiring an additional 5,357 shares during the period. Sei Investments Co. owned 0.18% of Eagle Pharmaceuticals worth $1,599,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Janus Henderson Group PLC acquired a new position in shares of Eagle Pharmaceuticals in the 2nd quarter valued at $144,384,000. Victory Capital Management Inc. increased its position in shares of Eagle Pharmaceuticals by 1.0% in the 3rd quarter. Victory Capital Management Inc. now owns 977,950 shares of the specialty pharmaceutical company’s stock valued at $58,325,000 after acquiring an additional 9,571 shares during the period. Thrivent Financial For Lutherans increased its position in shares of Eagle Pharmaceuticals by 17,917.8% in the 2nd quarter. Thrivent Financial For Lutherans now owns 828,820 shares of the specialty pharmaceutical company’s stock valued at $65,386,000 after acquiring an additional 824,220 shares during the period. State Street Corp boosted its holdings in Eagle Pharmaceuticals by 23.7% in the second quarter. State Street Corp now owns 696,466 shares of the specialty pharmaceutical company’s stock valued at $54,949,000 after purchasing an additional 133,601 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Eagle Pharmaceuticals by 22.7% in the second quarter. Vanguard Group Inc. now owns 561,820 shares of the specialty pharmaceutical company’s stock valued at $44,322,000 after purchasing an additional 103,760 shares during the last quarter.

Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) opened at $55.68 on Friday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.15 and a current ratio of 5.30. Eagle Pharmaceuticals, Inc. has a 12 month low of $45.05 and a 12 month high of $97.15. The stock has a market cap of $876.35, a PE ratio of 9.26 and a beta of 1.24.

EGRX has been the topic of several recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $75.00 price target (down from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. Mizuho reaffirmed a “sell” rating and issued a $37.00 price target on shares of Eagle Pharmaceuticals in a report on Wednesday, November 8th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $75.00 price target on shares of Eagle Pharmaceuticals in a report on Friday, October 27th. ValuEngine lowered shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Finally, BidaskClub raised shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 2nd. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average price target of $62.33.

ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/15/eagle-pharmaceuticals-inc-egrx-shares-bought-by-sei-investments-co.html.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply